Back to Authors

Arpey, Christopher J.

Mayo Clinic

Mayo Clinic in Arizona

Citations 11

A Case of Five Primary Microcystic Adnexal Carcinomas in a Young Adult
Smith, Sarah E. B. , Pittelkow, Mark, Arpey, Christopher, Arpey, Christopher J.

Dermatologic Surgery | July 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/dss.0000000000005273 Get It

Bovine Collagen Xenografts as Cost-Effective Adjuncts for Granulating Surgical Defects
Ladd, Ryan, Demer, Addison M. , Ochoa, Shari A. , Arpey, Christopher J., Demer, Addison, Ochoa, Shari, Arpey, Christopher

Dermatologic Surgery | May 9, 2024 | Volume: 50 | Issue: 9 | Pages: 884-886

10.1097/dss.0000000000004216 Get It

Immunosuppression is a risk factor for worse survival and disease‐specific death in cutaneous squamous cell carcinoma
Greene, Adina , Hwang, Angelina , Kechter, Jacob , Boudreaux, Blake W., Bhullar, Puneet , Severson, Kevin J. , Butterfield, Richard , Zhang, Nan , Tolaymat, Leila , Ochoa, Shari A. , Arpey, Christopher J., Baum, Christian L. , Mangold, Aaron R. , Mangold, A R , Hwang, Angelina S , Degesys, Catherine A.

JEADV Clinical Practice | October 12, 2023 | Volume: 3 | Issue: 1 | Pages: 182-190

10.1002/jvc2.265 Get It

AbstractBackgroundPrevious literature on cutaneous squamous cell carcinoma (cSCC) suggests that the incidence, rate of metastasis, and tumour severity of cSCC are higher in immunosuppressed patients than in immunocompetent patients. However, current literature lacks an extensive comparison of cSCC clinical characteristics and outcomes in immunosuppressed patients.ObjectivesWe compared cSCC tumour characteristics and disease‐related outcomes to help guide the clinical management of immunosuppressed patients.MethodsWe conducted a retrospective review of histopathologic and clinical data from 935 cSCC cases (19.5% immunosuppressed) from the Mayo Clinic.ResultsImmunosuppression was associated with younger age (69.3 vs. 74.8 years old, p < 0.0001), male gender (78.6% vs. 67.2%, p = 0.003), and higher grade cSCC tumour characterized by moderate or poor differentiation (25.7% vs. 15.8%, p = 0.009; 9.2% vs. 7.2%, p = 0.009, respectively). No significant differences were found in other tumour characteristics, including clinical tumour dimension, Brigham and Women's Hospital tumour staging or cumulative risk of metastasis and recurrence. Immunosuppressed patients had an increased risk of disease‐specific death on univariate analysis (hazard ratio [HR] [95% confidence interval, CI] 2.05 [1.13–3.74], p = 0.0128). Overall survival in the immunosuppressed population was worse (adjusted HR [95% CI] 1.83 [1.42–2.35], p < 0.001) and, notably, solid organ transplant recipients had the lowest overall survival when stratifying immunosuppressed patients by immunosuppression type (HR [95% CI] 1.62 [1.17–2.24], p < 0.0001).ConclusionsIn our study, immunosuppression status was predictive of poor differentiation of tumours and a reduction in overall and cSCC‐specific survival. Current staging systems for cSCC do not include immunosuppression as a risk factor and incorporating immune status may be beneficial for accurate risk stratification.
Safety of Oral Midazolam as a Perioperative Anxiolytic for Outpatient Dermatologic Procedures
Bezalel, Spencer A., Brewer, Jerry D., Baum, Christian L. , Arpey, Christopher J., Roenigk, Randall K., Otley, Clark C.

Dermatologic Surgery | August 21, 2020 | Volume: 46 | Issue: 12 | Pages: 1588-1592

10.1097/dss.0000000000002624 Get It

BACKGROUND Perioperative anxiety can negatively impact patient satisfaction and can complicate outpatient dermatologic procedures. OBJECTIVE Evaluate adverse events associated with oral midazolam as a perioperative anxiolytic during dermatologic surgery and assess whether an enhanced monitoring approach is associated with an increased detection rate. MATERIALS AND METHODS Five hundred cases (250 before and after change in monitoring) where patients were administered oral midazolam between July 2015 and May 2017 were retrospectively reviewed. The number of procedures, type of procedures, dose in milligrams, number of doses, major and minor adverse events, and vital signs were recorded. RESULTS The difference in number of treatment sites, types of procedures, and total dose administered was not significant. There were minor but significant differences in the mean change in blood pressure, heart rate, respiratory rate, and Richmond Agitation and Sedation Scale score before and after the procedure but not oxygen saturation. These vital sign changes were not clinically significant. There were zero major adverse events in both groups. There were 2 patients who became transiently hypoxic. CONCLUSION Oral midazolam administration was not associated with major adverse events including in the more intensively monitored group. This supports its use as an anxiolytic for outpatient dermatologic procedures.
Nasal Valve Insufficiency in Dermatologic Surgery
Barbosa, Naiara S. , Baum, Christian L. , Arpey, Christopher J.

Dermatologic Surgery | February 21, 2020 | Volume: 46 | Issue: 7 | Pages: 904-911

10.1097/dss.0000000000002310 Get It

BACKGROUND Few publications have addressed nasal valve (NV) insufficiency as a complication of Mohs micrographic surgery. OBJECTIVE To comprehensively review the literature and further characterize the causes, prevalence, evaluation, and management of NV insufficiency as it relates to cutaneous oncology. MATERIALS AND METHODS A PubMed search was completed to identify articles related to the NV in the context of Mohs micrographic surgery, cutaneous oncology, and reconstruction. RESULTS Nasal valve insufficiency may occur during tumor removal and/or reconstruction. Defect size larger than 1 cm; location on the ala, sidewall, or alar crease; lack of structural support; and poorly planned flaps are the main risk factors for NV insufficiency. Several surgical techniques have been described to avoid and correct this complication. CONCLUSION Nasal valve insufficiency may be an underrecognized and underreported complication of Mohs micrographic surgery. Nasal valve insufficiency may be identified with relatively simple tests. Knowledge of NV anatomy and preoperative function assessment is essential. Recognition of this potential complication and awareness of its prevention and management may decrease morbidity in patients undergoing cutaneous surgery.
Micrographic Surgery and Dermatologic Oncology Fellowship Selection Criteria
Arpey, Christopher J.

Dermatologic Surgery | June 12, 2019 | Volume: 45 | Issue: 10 | Pages: 1319-1320

10.1097/dss.0000000000001961 Get It

Patterns of failure following the excision of in‐transit lesions in melanoma and the influence of excisional margins
Gonzalez, Alexandra B., Baum, Christian L. , Brewer, Jerry D., Arpey, Christopher J., Harmsen, William S. , Jakub, James W. , Jakub, James W , Suman, Vera J. , Markovic, Svetomir N.

Journal of Surgical Oncology | August 16, 2018 | Volume: 118 | Issue: 4 | Pages: 606-613

10.1002/jso.25176 Get It

Background and ObjectivesTo describe the patterns of failure in patients with in‐transit (IT) melanoma undergoing surgical excision.MethodsA retrospective review of patients who underwent their first IT lesion(s) resection between May 2005 and September 2014. Cumulative incidence of local failure (new lesion within 2 cm of IT resection) was estimated. Associations between clinicopathologic characteristics, local failure, and any recurrence were analyzed.ResultsOne hundred and thirty patients presented to our institution with IT disease over the study period and met the inclusion criteria. The 2‐year cumulative incidence of local failure was 19.5%. Twenty‐four patients developed disease within 2 cm of the resected IT disease; however, only eight were isolated local events. Cumulative incidence of local failure and of any disease differed with respect to less than 1 year disease‐free interval (DFI) from primary melanoma to first IT event, and having greater than 1 IT lesion at presentation. Incidence of local failure was not found to differ with respect to gross margin greater than 5 mm, after adjusting for DFI and greater than 1 IT lesions.ConclusionsPatients with greater than 1 IT lesion and a DFI less than 1 year are at a higher risk of failure after surgical excision of a first IT event. Very few failures were isolated local disease within 2 cm of the IT resection scar, regardless of IT excision margin.
Surgical Treatment and Outcomes of Patients With Extramammary Paget Disease: A Cohort Study
Kim, Sharon J. , Thompson, Agnieszka K., Zubair, Adeel , Otley, Clark C. , Arpey, Christopher J., Baum, Christian L. , Roenigk, Randall K., Lohse, Christine M. , Brewer, Jerry D.

Dermatologic Surgery | February 10, 2017 | Volume: 43 | Issue: 5 | Pages: 708-714

10.1097/dss.0000000000001051 Get It

BACKGROUND Extramammary Paget disease (EMPD) is a rare intraepithelial adenocarcinoma occurring mainly in the anogenital region. Traditional management with wide local excision has shown high recurrence rates, thus Mohs micrographic surgery (MMS) has emerged as a promising treatment option. OBJECTIVE To compare long-term outcomes after treatment with MMS or excision for primary EMPD. METHODS AND MATERIALS Retrospective cohort review was conducted for 207 patients with EMPD treated at Mayo Clinic in Rochester, MN, between 1961 and 2012. RESULTS Of the 25 patients treated with MMS, 19 primary tumors were included for outcome analysis, with an estimated 5-year recurrence-free survival rate of 91% (95% confidence interval [CI], 75–100) using Kaplan–Meier curve analysis. Of 158 patients treated with local excision, 124 were included for the analysis, with an estimated 5-year recurrence-free survival rate of 66% (95% CI, 56–78). The hazard ratio (HR) for association of treatment was 0.4 (95% CI, 0.10–1.65; p = .20). Estimated 5-year overall survival rates were 79% for MMS (95% CI, 61–100) and 68% for excision (95% CI, 59–78) (HR, 1.39 [95% CI, 0.69–2.82]; p = .36). CONCLUSION Although treatment of primary EMPD with MMS versus excision did not show statistical difference, MMS demonstrated favorable long-term outcomes and was associated with a higher recurrence-free survival rate.
A Comparison of Mohs Micrographic Surgery and Wide Local Excision for Treatment of Dermatofibrosarcoma Protuberans With Long-Term Follow-up: The Mayo Clinic Experience
Lowe, Garrett C., Onajin, Oluwakemi , Baum, Christian L. , Otley, Clark C. , Arpey, Christopher J., Roenigk, Randall K., Brewer, Jerry D.

Dermatologic Surgery | October 5, 2016 | Volume: 43 | Issue: 1 | Pages: 98-106

10.1097/dss.0000000000000910 Get It

BACKGROUND Dermatofibrosarcoma protuberans (DFSP) is a soft tissue tumor with slow infiltrative growth and local recurrence if inadequately excised. OBJECTIVE To compare long-term outcomes after Mohs micrographic surgery (MMS) and wide local excision (WLE). MATERIALS AND METHODS Records of patients with DFSP surgically treated with WLE or MMS from January 1955 through March 2012 were retrospectively reviewed. RESULTS Mean follow-up for patients treated with MMS (n = 67) and WLE (n = 91) was 4.8 and 5.7 years, respectively. Twenty-eight patients (30.8%) with WLE had recurrence (mean, 4.4 years), whereas only 2 (3.0%) with MMS had recurrence (1.0 and 2.6 years). Recurrence-free survival rates at 1, 5, 10, and 15 years were significantly higher with MMS (p < .001). Mean preoperative lesion sizes were similar (5–6 cm) between the 2 groups, whereas mean (standard deviation) postoperative defect sizes were 10.7 (4.3) cm and 8.8 (5.5) cm for WLE and MMS, respectively (p = .004). Primary closure was used for 73% of MMS cases, whereas WLE more commonly used flaps, grafts, or other closures (52%). Two Mohs layers typically were required for margin control. CONCLUSION Surgical excision with meticulous histologic evaluation of all surgical margins is needed for DFSP treatment to achieve long-term high cure rates and low morbidity.
Comparison of Sterile vs Nonsterile Gloves in Cutaneous Surgery and Common Outpatient Dental Procedures
Brewer, Jerry D., Gonzalez, Alexandra B., Baum, Christian L. , Arpey, Christopher J., Roenigk, Randall K., Otley, Clark C. , Erwin, Patricia J.

JAMA Dermatology | August 3, 2016 | Volume: 152 | Issue: 9 | Pages: 1008

10.1001/jamadermatol.2016.1965 Get It